Pfizer drug Xeljanz (tofacitinib) is approved in the United States for adult patients in three indications: moderately to severely active rheumatoid arthritis (RA) after methotrexate failure, active psoriatic arthritis (PsA) after disease modifying antirheumatic drug (DMARD) failure and moderately to severely active ulcerative colitis (UC) after tumor necrosis factor inhibitor (TNFi) failure. MNG Tracker report title “Xeljanz Drug Sales & Forecast” provides historical as well as estimated Xeljanz sales in Global, United States and Rest of the World market. This is single page report which also covered key factors for the growth/decline of the Xeljanz sales in Global, United States and Rest of the World market.
MNG Tracker is a market research company which offer market research reports and database subscription service. Continuous tracking on latest changes in the industry and predict about the emerging needs, challenges and opportunities, is the essential needs for the growth of the business. MNG Tracker is exists for that. MNG Tracker is steadily monitored on the latest happening in the industries, companies and regulatory policies around the world. MNG Tracker is all about market, research and data. We know our clients; who they are, what they see and what they do. MNG Tracker team is fully dedicated to achieve their needs and expectation.
125/5D, Sector 5 Vrindavan Yojna,
Lucknow - 226002, India
Phone:+91 8527886312,
+ 91 7530849871
Email: info@mngtracker.com
FOLLOW USCOPYRIGHT © 2018 MNG Tracker. All Rights Reserved.